Table 1.
Subject demographics
| Subject characteristics | Neutralizers | Low-neutralizers | Non-neutralizers | Statistics | p-value | Total |
|---|---|---|---|---|---|---|
| Subjects (n) | 14 | 18 | 33 | 65 | ||
| Age range min-max (years) | 26–64 | 30–67 | 31–67 | 26–67 | ||
| Average age (years±SD) | 47±11 | 52±10 | 50±9 | One-way ANOVA | p=0.43 | 50±9 |
| Male (n, %) | 12, 86% | 16, 89% | 27, 82% | Chi-square | p=0.37 | 55, 85% |
| Race/ethnicity (n, %) | ||||||
| African American | 7, 50% | 5, 28% | 7, 21% | 19, 29% | ||
| Asian | 0, 0% | 0, 0% | 0, 0% | 0, 0% | ||
| Caucasians | 6, 43% | 13, 72% | 24, 73% | Chi-square | p=0.13 | 43, 66% |
| Hispanic | 0, 0% | 0, 0% | 2, 6% | 2, 3% | ||
| Other/unknown | 1, 7% | 0, 0% | 0, 0% | 1, 2% | ||
| Neutralization breadth (average, range) | 7.9, 5–11 | 2.0, 1–4 | 0.0,0 | B | B | 2, 0–11 |
| ART naïve (n, %) | 7, 50% | 12, 67% | 18, 55% | Chi-square | p=0.28 | 37, 57% |
| Time since diagnosis (years) | 18 | 19 | 16 | One-way ANOVA | p=0.93 | 17.4 |
| CD4 count (cells/µl) | 737 | 659 | 796 | Kruskal–Wallis | p=0.5 | 761 |
| Protective HLA-B genotype (n, %) | ||||||
| All subjects (n=65) B*27 ∣ B*57 | 4, 29% | 7, 39% | 19, 58% | Chi-square | p=0.11 | 30, 46% |
| VC only (n=41) B*27 ∣ B*57 | 4, 31% | 4, 33% | 8, 50% | Chi-square | p=0.5 | 16, 39% |
| Median viral load (copies/ml) | ||||||
| All subjects, EC & VC (n=65) | 400 | 87 | 67 | Kruskal–Wallis | p<0.010 | 141 |
| VC only (n=41) | 400 | 304 | 205 | Kruskal–Wallis | p=0.5 | 321 |
| Viral control category (n, %) | ||||||
| Elite | 1, 7% | 6, 33% | 17, 52% | Chi-square | p<0.050 | 24, 37% |
| Viremic | 13, 93% | 12, 67% | 16, 48% | 41, 63% |
p values in bold indicate significant differences.